サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427825

胃食道逆流症治療薬の世界市場レポート 2024

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
胃食道逆流症治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

胃食道逆流症治療薬の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.1%の年間複合成長率（CAGR）で73億3,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、新しい治療法に対する需要の増加、高齢者人口の増加、個別化医療アプローチの採用、非薬理学的介入への注目、生物学的製剤や革新的な治療法の出現に関連しています。予測期間中に予想される注目すべき動向には、代替療法と心身実践の探求、腸の健康に関する調査の拡大、患者中心のケアモデルのイントロダクション、胃食道逆流症に対する意識を高めるためのターゲットを絞ったマーケティング、デジタルヘルスツールの統合などが含まれます。

胃食道逆流症治療薬市場の予想される成長は、胃食道逆流症の蔓延によって促進されると予想されます。この慢性疾患は食道への胃酸の逆流を特徴とし、胸やけや逆流などの症状を引き起こします。胃食道逆流症（GERD）の治療薬は、腸内pHを中和し、炎症を制御し、食道の機能を改善することにより、これらの症状を軽減および管理するように設計されています。たとえば、2022年 9月のWebMedの記事では、6,000万人以上のアメリカ成人が少なくとも月に1回は胸やけを経験し、1,500万人以上が毎日症状を経験していると報告しました。さらに、国立医学図書館は2022年 7月に、米国における胃食道逆流症の有病率が20%と高く、多大な経済的負担を引き起こし、生活の質に影響を与えていることを示す統計を共有しました。したがって、胃食道逆流症の有病率の増加は、治療薬市場の成長を促進すると予想されます。

セルフメディケーションの導入は、胃食道逆流症治療薬市場の継続的な成長に重要な役割を果たしています。セルフメディケーションとは、ヘルスケア専門家に相談せずに、薬や物質を使用して病状を治療することを指します。この実践は、誘発食品の特定と管理、ストレスへの対処、禁煙において個人にとって有益であり、これらすべてが胃食道逆流症の症状の改善に貢献します。リッピンコット・ウィリアムズ＆ウィルキンスが2022年5月に170人の参加者を対象に実施した調査では、57.7％がセルフメディケーションを実践し、34.7％が医師に相談する必要はないと感じていることが明らかになった。したがって、セルフメディケーションの採用は、胃食道逆流症治療薬市場の促進要因になると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界の胃食道逆流症治療薬市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • ブランド
  • ジェネリック
  • 世界の胃食道逆流症治療薬市場、薬剤クラス別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 制酸薬
  • プロトンポンプ阻害剤
  • ヒスタミンブロッカー
  • プロキネティックエージェント
  • その他の薬剤クラス
  • 世界の胃食道逆流症治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • ドラッグストア
  • 雑貨店
  • スーパーマーケット
  • 世界の胃食道逆流症治療薬市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • クローン病
  • 胃食道逆流症（GERD）
  • 潰瘍性大腸炎

第7章 地域および国の分析

  • 世界の胃食道逆流症治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の胃食道逆流症治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 胃食道逆流症治療薬市場の競合情勢
  • 胃食道逆流症治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson and Johnson
    • Novartis AG
    • Sanofi SA
    • AstraZeneca plc

第31章 その他の大手および革新的な企業

  • Medtronic PLC
  • GlaxoSmithKline plc
  • Eisai Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • bioMerieux SA
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories Ltd.
  • Bruker Corp
  • Amneal Pharmaceuticals LLC
  • CHEPLAPHARM Arzneimittel GmbH
  • Daewoong Pharmaceutical Co. Ltd
  • Ironwood Pharmaceuticals Inc.
  • Sebela Pharmaceuticals Inc.
  • Camber Pharmaceuticals Inc.
  • Sun Pharmaceutical Industries Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13669

Gastroesophageal reflux disease (GERD) therapeutics encompass medications designed for the chronic medical condition characterized by the upward movement of stomach contents into the esophagus, leading to symptoms such as heartburn and regurgitation. These therapeutics aim to neutralize and diminish the production of stomach acid, maintaining an optimal pH level in the gut and preventing the backflow of fluids into the stomach that causes acid reflux.

The primary categories of gastroesophageal reflux disease therapeutics include branded and generic medications. Branded medications are those that can only be dispensed with a prescription from a physician or other authorized prescriber, adhering to state or federal regulations. These drugs are employed for the treatment of gastroesophageal reflux disease, aiming to alleviate symptoms and facilitate esophageal healing. Various drug classes, such as antacids, proton pump inhibitors, histamine blockers, pro-kinetic agents, among others, are distributed through diverse channels, including hospital pharmacies, drug stores, general stores, and supermarkets. These therapeutics find applications in conditions such as Crohn's disease, gastroesophageal reflux disease (GERD), and ulcerative colitis.

The gastroesophageal reflux disease therapeutics market research report is one of a series of new reports from The Business Research Company that provides gastroesophageal reflux disease therapeutics market statistics, including gastroesophageal reflux disease therapeutics industry global market size, regional shares, competitors with a gastroesophageal reflux disease therapeutics market share, detailed gastroesophageal reflux disease therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gastroesophageal reflux disease therapeutics industry. This gastroesophageal reflux disease therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.78 billion in 2023 to $6 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth observed in the historical period can be ascribed to shifts in lifestyles and dietary habits, an aging population, heightened awareness and diagnosis, prevalent stressful lifestyles, and an increase in obesity rates.

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The anticipated growth in the forecast period is linked to an increased demand for novel therapies, a growing geriatric population, the adoption of personalized medicine approaches, a focus on non-pharmacological interventions, and the emergence of biologics and innovative therapies. Notable trends expected in the forecast period include the exploration of alternative therapies and mind-body practices, expanded research into gut health, the introduction of patient-centric care models, targeted marketing to raise awareness about GERD, and the integration of digital health tools.

The anticipated growth in the gastroesophageal reflux disease therapeutics market is expected to be driven by the prevalence of gastroesophageal reflux disease. This chronic condition, characterized by the backflow of stomach acid into the esophagus, leads to symptoms such as heartburn and regurgitation. Gastroesophageal reflux disease (GERD) therapeutics are designed to reduce and manage these symptoms by neutralizing gut pH, controlling inflammation, and improving esophageal function. For example, a WebMed article in September 2022 reported that over 60 million American adults experience heartburn at least once a month, with more than 15 million experiencing daily symptoms. Additionally, the National Library of Medicine shared statistics in July 2022 indicating GERD's high prevalence of 20% in the United States, causing a significant economic burden and impacting quality of life. Hence, the increasing prevalence of gastroesophageal reflux disease is expected to fuel the growth of the therapeutics market.

The adoption of self-medication is playing a significant role in the continued growth of the gastroesophageal reflux disease therapeutics market. Self-medication involves using drugs or substances to treat a medical condition without consulting a healthcare professional. This practice is beneficial for individuals in identifying and managing trigger foods, handling stress, and quitting smoking, all of which contribute to improving GERD symptoms. A survey conducted in May 2022 by Lippincott Williams & Wilkins, involving 170 participants, revealed that 57.7% practiced self-medication, and 34.7% felt no need to consult a medical practitioner. Therefore, the adoption of self-medication is expected to be a driving factor in the gastroesophageal reflux disease therapeutics market.

Product innovations are a prominent trend gaining traction in the gastroesophageal reflux disease therapeutics market. Key players in the market are strategically focusing on introducing innovative medications to maintain their competitive position. For example, in March 2021, Xiromed LLC, an integrated generic company based in the United States, launched Omeprazole Delayed-Release Capsules, a generic version of Prilosec, designed to treat frequent heartburn associated with gastroesophageal reflux. Omeprazole, a proton pump inhibitor (PPI) medication, is formulated to address stomach and esophageal issues by reducing acid production, alleviating symptoms such as heartburn, difficulty swallowing, and persistent cough. This medication aids in healing acid damage, preventing ulcers, and may reduce the risk of esophageal cancer.

Major companies in the gastroesophageal reflux disease therapeutics market are directing their efforts toward the development of innovative systems, including wireless pH-capsule reflux testing systems. These medical devices are specifically designed for diagnosing and monitoring gastroesophageal reflux disease (GERD) and related conditions. For instance, in April 2023, Laborie Medical Technologies Corp., a U.S.-based medical testing equipment manufacturer, introduced the alpHaONE system, a wireless pH-capsule reflux testing system tailored for GERD diagnosis. Offering up to 96 hours of data monitoring, this system ensures accurate and reliable data. The alpHaONE system features an ergonomic and compact design, user-friendly enlarged buttons, and a fail-safe capsule delivery system designed to protect the patient's esophagus.

In October 2022, Evonik Industries AG, a Germany-based specialty chemicals company, entered into a partnership with Phathom Pharmaceuticals. This collaboration aims to enable Evonik to produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in the United States and Germany. Phathom Pharmaceuticals, a U.S.-based biopharmaceutical company, is dedicated to developing innovative medicines for stomach acid-related disorders, including drugs for gastroesophageal reflux disease.

Major companies operating in the gastroesophageal reflux disease therapeutics market report are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, GlaxoSmithKline PLC, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Bruker Corp, Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc., TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Addex Pharmaceuticals.

North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastroesophageal reflux disease therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastroesophageal reflux disease (GERD) therapeutics market consists of sales of amino-salicylates (5-ASA), corticosteroids, immunomodulators, antibiotics, biologics, and dopamine receptor antagonist. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastroesophageal reflux disease therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastroesophageal reflux disease therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroesophageal reflux disease therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Branded; Generic
  • 2) By Drug Class: Antacids; Proton Pump Inhibitors; Histamine Blockers; Pro-Kinetic Agents; Other Drugs Class
  • 3) By Distribution Channel: Hospital Pharmacy; Drug Stores; General Stores; Supermarkets
  • 4) By Application: Crohn's Disease; Gastroesophageal Reflux Disease (GERD); Ulcerative Colitis
  • Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Novartis AG; Sanofi S.A.; AstraZeneca plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastroesophageal Reflux Disease Therapeutics Market Characteristics

3. Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies

4. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Gastroesophageal Reflux Disease Therapeutics Market Size and Growth

  • 5.1. Global Gastroesophageal Reflux Disease Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Gastroesophageal Reflux Disease Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Gastroesophageal Reflux Disease Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gastroesophageal Reflux Disease Therapeutics Market Segmentation

  • 6.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Branded
  • Generic
  • 6.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antacids
  • Proton Pump Inhibitors
  • Histamine Blockers
  • Pro-Kinetic Agents
  • Other Drugs Class
  • 6.3. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Drug Stores
  • General Stores
  • Supermarkets
  • 6.4. Global Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Crohn's Disease
  • Gastroesophageal Reflux Disease (GERD)
  • Ulcerative Colitis

7. Gastroesophageal Reflux Disease Therapeutics Market Regional And Country Analysis

  • 7.1. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Gastroesophageal Reflux Disease Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market

  • 8.1. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gastroesophageal Reflux Disease Therapeutics Market

  • 9.1. China Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 9.2. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gastroesophageal Reflux Disease Therapeutics Market

  • 10.1. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gastroesophageal Reflux Disease Therapeutics Market

  • 11.1. Japan Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 11.2. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gastroesophageal Reflux Disease Therapeutics Market

  • 12.1. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gastroesophageal Reflux Disease Therapeutics Market

  • 13.1. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gastroesophageal Reflux Disease Therapeutics Market

  • 14.1. South Korea Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 14.2. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gastroesophageal Reflux Disease Therapeutics Market

  • 15.1. Western Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 15.2. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gastroesophageal Reflux Disease Therapeutics Market

  • 16.1. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gastroesophageal Reflux Disease Therapeutics Market

  • 17.1. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gastroesophageal Reflux Disease Therapeutics Market

  • 18.1. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gastroesophageal Reflux Disease Therapeutics Market

  • 19.1. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gastroesophageal Reflux Disease Therapeutics Market

  • 20.1. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market

  • 21.1. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 21.2. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gastroesophageal Reflux Disease Therapeutics Market

  • 22.1. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gastroesophageal Reflux Disease Therapeutics Market

  • 23.1. North America Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 23.2. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gastroesophageal Reflux Disease Therapeutics Market

  • 24.1. USA Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 24.2. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gastroesophageal Reflux Disease Therapeutics Market

  • 25.1. Canada Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 25.2. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gastroesophageal Reflux Disease Therapeutics Market

  • 26.1. South America Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 26.2. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gastroesophageal Reflux Disease Therapeutics Market

  • 27.1. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gastroesophageal Reflux Disease Therapeutics Market

  • 28.1. Middle East Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 28.2. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gastroesophageal Reflux Disease Therapeutics Market

  • 29.1. Africa Gastroesophageal Reflux Disease Therapeutics Market Overview
  • 29.2. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Gastroesophageal Reflux Disease Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Gastroesophageal Reflux Disease Therapeutics Market Competitive Landscape
  • 30.2. Gastroesophageal Reflux Disease Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson and Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Sanofi S.A.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. AstraZeneca plc
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Gastroesophageal Reflux Disease Therapeutics Market Other Major And Innovative Companies

  • 31.1. Medtronic PLC
  • 31.2. GlaxoSmithKline plc
  • 31.3. Eisai Co. Ltd.
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. bioMerieux SA
  • 31.6. Teva Pharmaceutical Industries
  • 31.7. Dr. Reddy's Laboratories Ltd.
  • 31.8. Bruker Corp
  • 31.9. Amneal Pharmaceuticals LLC
  • 31.10. CHEPLAPHARM Arzneimittel GmbH
  • 31.11. Daewoong Pharmaceutical Co. Ltd
  • 31.12. Ironwood Pharmaceuticals Inc.
  • 31.13. Sebela Pharmaceuticals Inc.
  • 31.14. Camber Pharmaceuticals Inc.
  • 31.15. Sun Pharmaceutical Industries Ltd.

32. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Benchmarking

33. Global Gastroesophageal Reflux Disease Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gastroesophageal Reflux Disease Therapeutics Market

35. Gastroesophageal Reflux Disease Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Gastroesophageal Reflux Disease Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Gastroesophageal Reflux Disease Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Gastroesophageal Reflux Disease Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer